Articles

Commentary: Developing Humanized Cancer Models for Cost-Effective and Productive Cancer Drug Discovery

Oncology drug discovery faces one of the highest attrition rates for drug candidates in the development pipeline, largely due to efficacy issues. More relevant clinical models, ones that better reflect cancer heterogeneity and disease progression, could address this problem.
Written byDr. Jean-Pierre Wery
Brought to you byanalytica
| 5 min read

Developing Humanized Cancer Models for Cost-Effective and Productive Cancer Drug Discovery – Targeting the Tumor Microenvironment

The drug discovery process is complex and protracted, and requires drug development companies and contract research organizations (CROs) to overcome numerous obstacles in preclinical and clinical development before achieving regulatory approval. As drug candidates progress, R&D costs increase sharply. In Oncology Drug Discovery, the attrition rate of candidates successfully traversing clinical trials and reaching the market is very high at over 90 percent, and 50 percent of these failures are down to lack of efficacy1.

Reducing these attrition rates underscores the need for improved clinical models, as well as their translation to clinical trial design, analysis and prediction. A significant limitation in developing drug candidates for oncology is the challenge of accessing relevant clinical models that truly mimic the diversity of a patient population and the stages of progression of a disease. As each tumor is unique and cancer progression is non-uniform across all patients, treatments need to be tailored to subtypes of cancer, making discovery and development more complex, time-consuming and costly.

A Personalized Approach to Drug Therapy

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.